21.05.2008 11:00:00
|
CONMED Corporation Appoints Joseph Darling President of the CONMED Linvatec Orthopedic Products Unit
CONMED Corporation (Nasdaq: CNMD) today announced that Joseph G.
Darling has been appointed President of the Company’s
CONMED Linvatec subsidiary, which specializes in surgical devices for
the repair of soft tissue injuries to joints often caused by sports
activity and is often referred to as Sports Medicine or Arthroscopy. The
unit, based in Largo, Florida, is also a market leader in Powered
Surgical Instruments for use by surgeons in orthopedics and a wide
variety of other specialties.
Most recently, Mr. Darling served as Senior Vice President & General
Manager at Smith & Nephew, Inc. where he was a member of the executive
leadership team with overall P&L responsibility for the sports medicine
business unit within the Endoscopy division. Prior to this role, Mr.
Darling served Smith & Nephew within the Endoscopy Division as Vice
President, Worldwide Marketing.
Prior to Smith & Nephew, Mr. Darling served Baxter International, Inc.
in a number of increasingly senior positions over a six year period. His
final position at Baxter was Vice President, Marketing II & Integrated
Delivery Network Sales within the Medication Delivery Systems division.
Mr. Darling began his career at Abbott Laboratories, where he spent
approximately 14 years in a number of increasingly senior positions. In
his final position at Abbott, Mr. Darling served as Director of Sales
within the Pharmaceutical Products Division. In this role, he directed
the sales, marketing and training efforts of large primary care and
specialty sales organizations.
"CONMED Corporation is fortunate to have Joe
join our organization. His diverse 25-year career in the medical
products industry has been marked by increasing levels of responsibility
in sales, marketing, development, and operations. He will lead a
world-wide team committed to the highest level of service to our
customers,” noted Mr. Joseph J. Corasanti,
President and CEO of CONMED Corporation.
Commenting on his appointment, Mr. Darling said, "CONMED
Corporation and the CONMED Linvatec organization have a premier
reputation in the medical device industry and I am excited to join such
a well-regarded team. I look forward to helping guide the Company in
achieving its growth objectives.”
Mr. Darling received his B.A. degree in Political Science from Syracuse
University.
CONMED Profile
CONMED is a medical technology company with an emphasis on surgical
devices and equipment for minimally invasive procedures and monitoring.
The Company’s products serve the clinical
areas of arthroscopy, powered surgical instruments, electrosurgery,
cardiac monitoring disposables, endosurgery and endoscopic technologies.
They are used by surgeons and physicians in a variety of specialties
including orthopedics, general surgery, gynecology, neurosurgery, and
gastroenterology. Headquartered in Utica, New York, the Company’s
3,200 employees distribute its products worldwide from several
manufacturing locations.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.
Nachrichten zu Conmed Corp.mehr Nachrichten
29.10.24 |
Ausblick: Conmed legt die Bilanz zum abgelaufenen Quartal vor (finanzen.net) | |
15.10.24 |
Erste Schätzungen: Conmed stellt Zahlen zum jüngsten Quartal vor (finanzen.net) | |
30.07.24 |
Ausblick: Conmed informiert über die jüngsten Quartalsergebnisse (finanzen.net) | |
16.07.24 |
Erste Schätzungen: Conmed präsentiert Bilanzzahlen zum jüngsten Jahresviertel (finanzen.net) |
Analysen zu Conmed Corp.mehr Analysen
Aktien in diesem Artikel
Conmed Corp. | 69,00 | 0,00% |
Indizes in diesem Artikel
S&P 600 SmallCap | 935,46 | -0,94% |